Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06611072Not ApplicableRecruiting

OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study

Role: lead

NCT07259616Completed

Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities

Role: lead

NCT03458221Phase 2Recruiting

Signal TrAnsduction Pathway Activity Analysis in OVarian cancER

Role: lead

NCT05174377Unknown

CADx - Radiomics to Distinguish the Origin of Ovarian Tumors

Role: lead

NCT04022863Unknown

Ovarium Cancer Detection by TEP's and ctDNA

Role: lead

NCT02281487Not ApplicableCompleted

Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy

Role: lead

All 6 trials loaded